{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:19:55Z","timestamp":1773415195777,"version":"3.50.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Funding Acknowledgements<\/jats:title>\n                  <jats:p>Type of funding sources: Public grant(s) \u2013 EU funding. Main funding source(s): R.A. has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under Marie-Curie grant agreement N\u00ba 847635.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Vitamin D (vitD) deficiency is highly prevalent in patients with pulmonary arterial hypertension (PAH). Moreover, PAH-patients with lower levels of vitD have worse prognosis. We demonstrated that in animals with PAH and severe deficit of vitD, restoring vitD levels to an optimal range partially improves some pathophysiological features of PAH. Also, recent evidence suggests that vitD deficiency may cause insufficient response to phosphodiesterase-5 inhibitors (PDE5i), such as sildenafil, in some patients with PAH. Thus, in this study, we hypothesize that the recovery of optimal vitD levels in experimental PAH might help to improve responsiveness to PDE5i therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Male Wistar rats were fed a vitD-free diet for five weeks and then received a single dose of Su5416 (20 mg\/Kg) and were exposed to vitD-free diet and chronic hypoxia (10% O2) for three weeks to induce PAH. Following this, vitD deficient rats with PAH were housed in room air and divided into two groups: (a) daily tadalafil therapy (oral;10mg\/kg) + continued vitD-free diet (n=9) or (b) daily tadalafil therapy (oral;10mg\/kg) + single oral dose of 50,000 IU\/Kg of vitD plus standard diet (n=9) for four weeks. Animals were then used for exercise capacity evaluation, invasive haemodynamic, pulmonary vascular analysis, and sample collection. Evolution of cardiac (dys)function was assessed by echocardiography.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Recovering optimal vitD levels improved pulmonary endothelial function, measured by an increase in the endothelium-dependent vasodilator response to acetylcholine. It also increased the vasodilator response to sildenafil. Moreover, pulmonary small artery (&amp;lt;55 \u00b5m) remodeling was decreased in vitD-restored group, as measured by a decline in mean lumen\/total ratio and mean medial thickness. In a morphometric analysis, vitD treatment attenuated increases in both right ventricle (RV) and right atrial hypertrophy, as well as the fulton index. VitD supplementation also improved the exercise capacity with increases seen in distance run, evaluated by endurance tests in a treadmill set. RV catheterization showed that vitD did not decreased the RV dysfunction, evaluated by end-systolic and end-diastolic pressure. Similar to the RV, no alterations were observed in pulmonary artery pressures. However, echocardiographic analysis revealed an improved pulmonary flow in the vitD-restored group, where pulmonary artery acceleration time normalized to ejection time ratio and pulmonary artery velocity-time integral were increased. It also improved tricuspid annular plane systolic excursion (TAPSE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Altogether, these data suggest that in animals with PAH treated with tadalafil, restoring vitD levels to an optimal range improves some pathophysiological features of PAH. Therefore, in addition to recovery of optimal vitD status being indicated to restore calcium homeostasis in those PAH patients with severe deficiency, it might help to improve responsiveness to PDE5i.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvae088.187","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T01:06:47Z","timestamp":1716944807000},"source":"Crossref","is-referenced-by-count":1,"title":["Recovery of optimal vitamin D improves responsiveness to phosphodiesterase-5 inhibitors therapy in pulmonary arterial hypertension"],"prefix":"10.1093","volume":"120","author":[{"given":"R","family":"Adao","sequence":"first","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]},{"given":"E","family":"Paternoster","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]},{"given":"B","family":"Barreira","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]},{"given":"D","family":"Morales-Cano","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]},{"given":"M A","family":"Olivencia","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]},{"given":"B","family":"Quintana-Villamandos","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]},{"given":"F","family":"Perez-Vizcaino","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid, Department of Pharmacology and Toxicology, School of Medicine , Madrid , Spain"}]}],"member":"286","published-online":{"date-parts":[[2024,5,29]]},"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/120\/Supplement_1\/cvae088.187\/57953623\/cvae088.187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/120\/Supplement_1\/cvae088.187\/57953623\/cvae088.187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T01:06:47Z","timestamp":1716944807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/doi\/10.1093\/cvr\/cvae088.187\/7683941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":0,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2024,5,29]]},"published-print":{"date-parts":[[2024,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvae088.187","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,5]]},"article-number":"cvae088.187"}}